Negative PD-L1 expression and successful treatment outcomes remind us to explore other features of the immune microenvironment, such as tumor mutation burden (TMB), microsatellite instability (MSI), and tumor-infiltrating T lymphocytes (TILs) (34, 59, 60). The gene discussed is CD274; the disease is neoplasm.